

Department of Dermatology

Publications

Peter Chien, MD

Safety and Efficacy of Non-Steroidal Topical Aryl Hydrocarbon Receptor Agonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Cevallos-Cueva M, Neto CAML, Martani D, Ghanem L, Sardinha CA, Mendoza-Millán DL, Gutu CS, Pungirum VB, **Chien P**. Australas J Dermatol. 2025 Apr 7. doi: 10.1111/ajd.14485. Epub ahead of print. PMID: 40192236.

Hye Jin Chung, MD

Lasers Versus Needle-Based Devices for Poly-L-Lactic Acid Delivery: An Optical Coherence Tomography and Histology Study. Suwan PT, Ahn GR, Manstein D, Ugwu N, **Chung HJ**. Ablative Fractional. Dermatol Surg. 2025 Apr 2. doi: 10.1097/DSS.0000000000004631. Epub ahead of print. PMID: 40172072.

Christopher Iriarte, MD

Immunotherapy-associated bullous and oral erosive lichenoid eruption successfully treated with hydroxychloroquine. Alnajjar NF, Tahan SR, **Iriarte C**. JAAD Case Rep. 2024 Nov 24;56:63-66. doi: 10.1016/j.jdcr.2024.11.010. PMID: 39886602; PMCID: PMC11779660.

William Lewis, MD

New onset Behçet's disease in repeat pregnancy. Xie L, Benson T, Morgan EE, **Lewis W**, Kotzin JJ, Craig E, Rosenbach M. JAAD Case Rep. 2025 Jan 29;58:106-108. doi: 10.1016/j.jdcr.2024.10.040. PMID: 40224218; PMCID: PMC11986486.

Department of Dermatology

Publications

Alexa Kimball, MD, and Martina Porter, MD

Cumulative life course impairment: Evidence for hidradenitis suppurativa. Doroudian Tehrani M, Gibson RS, Snyder CL, **Porter ML, Kimball AB**. J Eur Acad Dermatol Venereol. 2025 Mar 11. doi: 10.1111/jdv.20607. Epub ahead of print. PMID: 40065664.

Hidradenitis Suppurativa Epidemiology. Look-Why SL, Kirimlishvili S, **Porter ML, Kimball AB**. Dermatol Clin. 2025 Apr;43(2):145-154. doi: 10.1016/j.det.2024.12.001. Epub 2025 Jan 8. PMID: 40023617.

C-Reactive Protein and Response to Adalimumab in Patients With Hidradenitis Suppurativa: A Post Hoc Analysis of 2 Randomized Clinical Trials. Gunter SJ, **Porter ML, Kimball AB**. JAMA Dermatol. 2025 Feb 1;161(2):221-223. doi: 10.1001/jamadermatol.2024.5146. PMID: 39775706; PMCID: PMC11840640.

Alexa Kimball, MD

Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study. Ackerman LS, Schlosser BJ, Zhan T, Prajapati VH, Fretzin S, Takahashi H, Huang X, Camp HS, **Kimball AB**. J Am Acad Dermatol. 2025 Feb 4:S0190-9622(25)00190-2. doi: 10.1016/j.jaad.2024.12.046. Epub ahead of print. PMID: 39909350.

Adam Raff, MD

Immune Checkpoint Agonists for Inflammatory Skin Diseases. Vesely MD, Lizzul PF, Klekotka P, Joller N, **Raff A**. J Invest Dermatol. 2025 Feb 8:S0022-202X(25)00031-4. doi: 10.1016/j.jid.2025.01.008. Epub ahead of print. PMID: 39927905.